[HTML][HTML] Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature
Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …
Angiogenesis inhibition by the maleimide-based small molecule GNX-686
P Nowak-Sliwinska, M Storto, T Cataudella… - Microvascular …, 2012 - Elsevier
We investigated the anti-angiogenic properties of GNX-686, a newly identified maleimide-
based small molecule. In vitro studies on HUVEC showed that GNX-686 inhibited cell …
based small molecule. In vitro studies on HUVEC showed that GNX-686 inhibited cell …
[HTML][HTML] Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib
failure at Seoul National University Hospital between August 2005 and November 2011 …
failure at Seoul National University Hospital between August 2005 and November 2011 …
[HTML][HTML] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - Elsevier
PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …
[PDF][PDF] 厄洛替尼治疗吉非替尼控制后失败的晚期肺腺癌患者的可行性
张子瑾， 张萍， 武晓楠， 李琳… - 中国医学科学院 …, 2010 - journal13.magtechjournal.com
目的评价厄洛替尼用于既往吉非替尼控制后失败的晚期肺腺癌患者的可行性.
方法回顾性分析我院12 例厄洛替尼用于既往吉非替尼控制后失败的晚期肺腺癌患者的疗效 …
方法回顾性分析我院12 例厄洛替尼用于既往吉非替尼控制后失败的晚期肺腺癌患者的疗效 …
Hardware synthesis for reconfigurable heterogeneous pipelined accelerators
L Jozwiak, A Douglas - Fifth International Conference on …, 2008 - ieeexplore.ieee.org
This paper discusses a method of hardware synthesis for re-configurable heterogeneous
pipelined accelerators and corresponding EDA-tool that we developed. To evaluate the …
pipelined accelerators and corresponding EDA-tool that we developed. To evaluate the …
Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
Y Wan, Y Yuan, Y Pan, Y Zhang - Experimental and …, 2017 - spandidos-publications.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated
efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). However, their …
efficacy in the treatment of advanced non-small cell lung cancer (NSCLC). However, their …
[HTML][HTML] The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib
F Grossi, E Rijavec, MG Dal Bello, C Defferrari… - Cancer chemotherapy …, 2012 - Springer
Purpose Recent studies have demonstrated that erlotinib therapy may be considered an
option for patients with advanced non-small-cell lung cancer who experienced disease …
option for patients with advanced non-small-cell lung cancer who experienced disease …
[HTML][HTML] 吉非替尼耐药后加量疗法对比更换厄洛替尼治疗晚期非小细胞肺癌的临床观察
江昊， 周涛， 高亚杰， 刘基巍， 董岩 - 肿瘤防治研究, 2014 - zlfzyj.com
目的观察吉非替尼常规剂量耐药的晚期非小细胞肺癌患者加量应用吉非替尼或更换厄洛替尼的
疗效. 方法选择2007 年6 月—2012 年5 月大连医科大学附属第一医院收治的40 …
疗效. 方法选择2007 年6 月—2012 年5 月大连医科大学附属第一医院收治的40 …
Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: a retrospective study
S Yu, Y Wang, J Li, X Hao, B Wang, Z Wang… - Thoracic …, 2013 - Wiley Online Library
Background: The optimal strategy was not established for patients who initially responded to
gefitinib although re‐administration of epidermal growth factor receptor (EGFR) tyrosine …
gefitinib although re‐administration of epidermal growth factor receptor (EGFR) tyrosine …